



angioblast
systems

FDA GRANTS ORPHAN DRUG DESIGNATION FOR USE OF PROPRIETARY STEM CELLS IN BONE MARROW TRANSPLANTS

*Opportunity for accelerated product
commercialization and market exclusivity*

Key Points

- Bone marrow transplants represent new market opportunity
- Orphan drug designation allows for quicker product registration
- Fast-track program may translate to earlier revenues
- FDA to guide on size, timing and scope of registration trial

New York, USA; 17 September 2008: Angioblast Systems Inc., announced today that the United States Food and Drug Administration (FDA) has granted an orphan drug designation for the use of the patented adult stem cell technology in patients undergoing bone marrow transplantation.

The FDA awarded Angioblast Systems, Inc. the right to use the proprietary "off-the-shelf" allogeneic mesenchymal precursor cells for insufficient haematopoietic stem cell production in patients with hematologic malignancies who have failed treatment with conventional chemotherapy.

According to the March issue of *Biology and Bone Marrow Transplantation*, the probability that an individual in the United States will require a haematopoietic stem cell bone marrow transplant sometime during their life is 1 in 217. The FDA's orphan drug designation is reserved for new drugs or therapies being developed to treat diseases or conditions affecting less than 200,000 patients annually in the United States. Orphan drug designation allows for an accelerated review process by the FDA, seven-year market exclusivity in the United States upon obtaining marketing authorization, tax benefits, and exemption from user fees.

Hematopoietic stem cells are used to regenerate bone marrow in patients whose own bone marrow is damaged and destroyed by treatments for various

cancers. The greater the number of haematopoietic stem cells transplanted, the greater the likelihood that the bone marrow transplant will successfully engraft and regenerate a patient's damaged bone marrow.

In preclinical studies, the patented allogeneic mesenchymal precursor cells have been shown to significantly expand the number of haematopoietic stem cells in culture. The results of these studies formed the basis for the successful orphan drug submission to the FDA.

Angioblast's President and Founder, Professor Silviu Itescu, said the orphan drug designation was a significant milestone for the platform stem cell technology.

"It broadens the potential commercial applications to conditions requiring repair and regeneration of bone marrow, including various cancers and genetic diseases," he said.

"Significantly, orphan drug designation for our cells in these conditions may facilitate earlier revenues and market exclusivity," Professor Itescu added.

About Angioblast Systems, Inc.

Angioblast Systems, Inc. is a private New York City based biotechnology company committed to the development of novel treatments for cardiac, vascular, and eye conditions. Angioblast's lead products are based on commercialization of a unique adult stem cell technology capable of regulating blood vessel growth critical for the treatment of ischemic heart disease and macular degeneration/diabetic eye disease. Our focus is to progress through clinical trials and regulatory processes necessary to commercialize the technology in as short a timeframe as possible. Angioblast has the worldwide assignment of rights for a series of patents and technologies that have been developed over more than 10 years and which relate to the identification, extraction, culture expansion and enablement of adult Mesenchymal Precursor Cells (MPCs). Angioblast's strategy is to maximize shareholder value through both corporate partnerships and the rapid and successful completion of clinical milestones.

For further information please contact

Michael Schuster, MS, MBA
Vice President of Operations
T: (212) 880-2060
E: michael.schuster@angioblast.com
W: www.angioblast.com